

AMENDMENTS TO THE SPECIFICATION:

Please amend the paragraph that begins on page 7, line 1 as follows:

A further object of the invention is the use for the above purposes of the compounds known as ~~Crixivan®~~ CRIXIVAN® (indinavir) marketed by Merck, Sharp and Dohme; ~~Invirase®~~ INVIRASE® (saquinavir) or ~~Fortovase®~~ FORTOVASE® (saquinavir), marketed by Roche; ~~Norvir®~~ NORVIR® (ritonavir), marketed by Abbott Laboratories; ~~Viracept®~~ VIRACEPT® (nelfinavir), marketed by Roche; ~~Agenerase®~~ AGENERASE® (amprenavir), marketed by Glaxo Wellcome; ~~Kaletra®~~ KALETRA® (lopinavir and ritonavir), marketed by Abbott Laboratories.

Please amend the paragraph that begins on page 7, line 22 as follows:

Figure 1 (panels A ~~[[e]]~~ and B). Indinavir and saquinavir have no effect on the basal or bFGF-induced proliferation of primary macrovascular (~~humbeical~~ umbilical vein) endothelial cells. Panel A: effect of ~~indinavir~~ indinavir on basal or bFGF-induced cell proliferation; Panel B: effect of saquinavir on basal or bFGF-induced cell proliferation.